Mohammad Amin Karimi, Razieh Khadem, Alireza Haraj, Mehdi Azizabadi Farahani, Pardis Charehsaz Avari Firouzeh, Arash Azizinezhad, Hasti Kianpour Raki, Mohaddeseh Belbasi, Melika Arab Bafrani, Niloofar Deravi, Yaser Khakpour, Ali Faghih Habibi, Vahid Aghsaghloo
{"title":"钠-葡萄糖共转运蛋白2抑制剂对乳腺癌和癌症相关死亡率的影响：随机对照试验的系统回顾和荟萃分析","authors":"Mohammad Amin Karimi, Razieh Khadem, Alireza Haraj, Mehdi Azizabadi Farahani, Pardis Charehsaz Avari Firouzeh, Arash Azizinezhad, Hasti Kianpour Raki, Mohaddeseh Belbasi, Melika Arab Bafrani, Niloofar Deravi, Yaser Khakpour, Ali Faghih Habibi, Vahid Aghsaghloo","doi":"10.1186/s12885-025-14304-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>SGLT-2 inhibitors (SGLT-2i) lower blood glucose levels in type 2 diabetes by inhibiting renal glucose reabsorption. While the relationship between SGLT-2i and breast cancer remains inconclusive, emerging evidence suggests potential anticancer properties. This systematic review and meta-analysis compares the effects of SGLT-2i and DPP-4i on breast cancer incidence and related mortality to clarify current conflicting evidence.</p><p><strong>Methods: </strong>An extensive literature search was conducted using MeSH terms and relevant keywords related to SGLT-2 inhibitors, breast cancer, and mortality across PubMed, Scopus, and Google Scholar up to August 12, 2023. Additionally, reference lists of the included studies were manually screened to identify further eligible articles. Data on the impact of SGLT-2 inhibitors on breast cancer and its associated mortality were extracted from the included studies. Findings were presented using hazard ratios (HR) with 95% confidence intervals (CI) displayed in a forest plot. At the same time, heterogeneity was assessed using the I² statistic, applying a random-effects model for significant heterogeneity.</p><p><strong>Results: </strong>Seven cohort studies involving 408,026 individuals were included. SGLT-2 inhibitors were not associated with a significant difference in breast cancer risk compared to DPP-4 inhibitors (HR = 1.03, 95% CI: 0.82-1.30, p > 0.05), but were linked to a 30% reduction in breast cancer-specific mortality and improved overall survival (HR = 0.71, 95% CI: 0.65-0.77, p < 0.05).</p><p><strong>Conclusions: </strong>The impact of SGLT-2 inhibitors and DPP-4 inhibitors on breast cancer incidence appears to be comparable. However, SGLT-2 inhibitors may confer a greater reduction in breast cancer-related mortality and potentially improve overall patient survival compared to DPP-4 inhibitors. Given the observed heterogeneity among existing studies, larger, high-quality randomized controlled trials are warranted to validate these findings.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"991"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135325/pdf/","citationCount":"0","resultStr":"{\"title\":\"The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials.\",\"authors\":\"Mohammad Amin Karimi, Razieh Khadem, Alireza Haraj, Mehdi Azizabadi Farahani, Pardis Charehsaz Avari Firouzeh, Arash Azizinezhad, Hasti Kianpour Raki, Mohaddeseh Belbasi, Melika Arab Bafrani, Niloofar Deravi, Yaser Khakpour, Ali Faghih Habibi, Vahid Aghsaghloo\",\"doi\":\"10.1186/s12885-025-14304-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>SGLT-2 inhibitors (SGLT-2i) lower blood glucose levels in type 2 diabetes by inhibiting renal glucose reabsorption. While the relationship between SGLT-2i and breast cancer remains inconclusive, emerging evidence suggests potential anticancer properties. This systematic review and meta-analysis compares the effects of SGLT-2i and DPP-4i on breast cancer incidence and related mortality to clarify current conflicting evidence.</p><p><strong>Methods: </strong>An extensive literature search was conducted using MeSH terms and relevant keywords related to SGLT-2 inhibitors, breast cancer, and mortality across PubMed, Scopus, and Google Scholar up to August 12, 2023. Additionally, reference lists of the included studies were manually screened to identify further eligible articles. Data on the impact of SGLT-2 inhibitors on breast cancer and its associated mortality were extracted from the included studies. Findings were presented using hazard ratios (HR) with 95% confidence intervals (CI) displayed in a forest plot. At the same time, heterogeneity was assessed using the I² statistic, applying a random-effects model for significant heterogeneity.</p><p><strong>Results: </strong>Seven cohort studies involving 408,026 individuals were included. SGLT-2 inhibitors were not associated with a significant difference in breast cancer risk compared to DPP-4 inhibitors (HR = 1.03, 95% CI: 0.82-1.30, p > 0.05), but were linked to a 30% reduction in breast cancer-specific mortality and improved overall survival (HR = 0.71, 95% CI: 0.65-0.77, p < 0.05).</p><p><strong>Conclusions: </strong>The impact of SGLT-2 inhibitors and DPP-4 inhibitors on breast cancer incidence appears to be comparable. However, SGLT-2 inhibitors may confer a greater reduction in breast cancer-related mortality and potentially improve overall patient survival compared to DPP-4 inhibitors. Given the observed heterogeneity among existing studies, larger, high-quality randomized controlled trials are warranted to validate these findings.</p>\",\"PeriodicalId\":9131,\"journal\":{\"name\":\"BMC Cancer\",\"volume\":\"25 1\",\"pages\":\"991\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135325/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12885-025-14304-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-14304-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
The impact of sodium-glucose cotransporter-2 inhibitors on breast cancer and cancer-related mortality: a systematic review and meta-analysis of randomized controlled trials.
Background: SGLT-2 inhibitors (SGLT-2i) lower blood glucose levels in type 2 diabetes by inhibiting renal glucose reabsorption. While the relationship between SGLT-2i and breast cancer remains inconclusive, emerging evidence suggests potential anticancer properties. This systematic review and meta-analysis compares the effects of SGLT-2i and DPP-4i on breast cancer incidence and related mortality to clarify current conflicting evidence.
Methods: An extensive literature search was conducted using MeSH terms and relevant keywords related to SGLT-2 inhibitors, breast cancer, and mortality across PubMed, Scopus, and Google Scholar up to August 12, 2023. Additionally, reference lists of the included studies were manually screened to identify further eligible articles. Data on the impact of SGLT-2 inhibitors on breast cancer and its associated mortality were extracted from the included studies. Findings were presented using hazard ratios (HR) with 95% confidence intervals (CI) displayed in a forest plot. At the same time, heterogeneity was assessed using the I² statistic, applying a random-effects model for significant heterogeneity.
Results: Seven cohort studies involving 408,026 individuals were included. SGLT-2 inhibitors were not associated with a significant difference in breast cancer risk compared to DPP-4 inhibitors (HR = 1.03, 95% CI: 0.82-1.30, p > 0.05), but were linked to a 30% reduction in breast cancer-specific mortality and improved overall survival (HR = 0.71, 95% CI: 0.65-0.77, p < 0.05).
Conclusions: The impact of SGLT-2 inhibitors and DPP-4 inhibitors on breast cancer incidence appears to be comparable. However, SGLT-2 inhibitors may confer a greater reduction in breast cancer-related mortality and potentially improve overall patient survival compared to DPP-4 inhibitors. Given the observed heterogeneity among existing studies, larger, high-quality randomized controlled trials are warranted to validate these findings.
期刊介绍：
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
